title: Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.
abstract: Much is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection.
  
  
  OBJECTIVE
  Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA University of Washington, Department of Global Health, Seattle, Washington, USA.
authors.forename: Kristen
authors.initials: K
authors.lastname: Cohen
authors.affiliation: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA Heinrich-Pette-Institut, Hamburg, Germany.
authors.forename: Marcus
authors.initials: M
authors.lastname: Altfeld
authors.affiliation: Ragon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors.forename: Galit
authors.initials: G
authors.lastname: Alter
authors.affiliation: Seattle Biomedical Research Institute, Seattle, Washington, USA University of Washington, Department of Global Health, Seattle, Washington, USA leo.stamatatos@seattlebiomed.org.
authors.forename: Leonidas
authors.initials: L
authors.lastname: Stamatatos
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D001402:B-Lymphocytes / Q000276:immunology*; D015331:Cohort Studies; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D008137:Longitudinal Studies; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis; D054380:Receptors, CXCR5 / Q000032:analysis; D016176:T-Lymphocyte Subsets / Q000737:chemistry / Q000276:immunology*; D006377:T-Lymphocytes, Helper-Inducer / Q000737:chemistry / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; C095085:CXCR5 protein, human; D015483:HIV Antibodies; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D054380:Receptors, CXCR5